Can-Fite Announces Late-Breaking Abstract Presentation on Namodenoson(TM) Phase II Results at the American Association of Clinical Oncology (ASCO) Annual Meeting
Stock Information for Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Loading
Please wait while we load your information from QuoteMedia.